A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly

Acromegaly is a rare condition usually caused by a non-cancerous growth on the pituitary gland in the brain. This growth causes the body to produce too much growth hormone, which then prompts the liver to make high levels of a protein known as IGF-1. Over time, high IGF-1 levels can cause bones and soft tissues to grow, leading to enlarged hands, feet, and facial features, as well as joint pain, headaches, and extreme tiredness.

The most common medical treatments for acromegaly are monthly injections called somatostatin analogues, such as lanreotide or octreotide. These medicines help block the release of growth hormone. However, for many people, these standard treatments alone do not lower IGF-1 levels enough to manage symptoms or protect long-term health.

This trial is looking at ALXN2420, an experimental medicine designed to work in a different way. Instead of stopping the brain from releasing growth hormone, it blocks growth hormone from attaching to cells throughout the body. By adding ALXN2420 to standard monthly injections, researchers hope to give patients better hormone control. The study compares different doses of the new drug against a placebo (an inactive dummy jab) to find the safest and most effective dose.